Aggrega Pharma, LLC is a specialty generic pharmaceutical company dedicated to the development, manufacturing, and marketing of niche, complex, and high-barrier-to-entry generic medications for the US market. The company focuses on various finished dosage forms, including injectable, ophthalmic, extended and immediate-release oral, transdermal, spray, and topical formulations. Aggrega Pharma is backed by four European companies—Bluepharma (Portugal), Rafarm (Greece), Substipharm (France), and Welding (Germany)—and is committed to building a selective and valuable pipeline of generic products by leveraging the extensive R&D, clinical, and manufacturing expertise of its shareholders.

Services include:
– Finished Dosage Forms
– Active Pharmaceutical Ingredients
– Contract Manufacturing (CMO/CDMO)
– Packaging

Aggrega Pharma, LLC continues to seek opportunities for expanding and enhancing its finished dose portfolio through collaborative partnerships, offering flexible business models to strengthen products while minimising risk. For more information, visit aggregapharma.com.